bit.bio to showcase its ioCRISPR-Ready CellsTM products at the SLAS 2024 international conference and exhibition

Dr. Farah Patell-Socha, VP research products, bit.bioWith our ioCRISPR-Ready Cells, we're providing scientists with a powerful functional genomics tool to study any gene of interest in a defined human iPSC-derived cell system. Gene knockout experiments such as CRISPR screens that would previously require substantial time and specialised skills can now be undertaken in weeks by scientists with all levels of experience. We are excited to share these data at SLAS and to discuss the tremendous potential that this product range offers.

• CRISPR-Ready ioGlutamatergic Neurons: a functional genomics tool to easily generate disease-specific models for drug discovery and development. Poster Session C, Tuesday 6 February, 12-1pm. Track: Assay Development and Screening. This product was launched by bit.bio in October 2023. 
• CRISPR knockout screening for drug target identification and validation using CRISPR-Ready ioMicroglia. Poster Session D, Tuesday 6 February, 2-3 pm. Track: Cellular Technologies. This is the next product in the ioCRISPR-Ready Cells range that will launch in 2024. 

All bit.bio ioCells^TM products, including ioCRISPR-Ready Cells, are precision reprogrammed using bit.bio’s opti-ox^TM technology. As such, they are defined as human cells that have inherent experimental scalability, offer unparallelled consistency and are simple to handle and culture.

• Speakers:  Rob Howes, PhD - Head of Discovery Sciences UK at Charles River Laboratories Davide Gianni, PhD - Senior Director Functional Genomics, Discovery Sciences, BioPharmaceuticals R&D at AstraZeneca Josh Tycko, PhD - Research Fellow in Neurobiology at Harvard Medical School Ann Byrne, PhD - Functional Genomics at bit.bio
• Date and time: Tuesday 3rd February 8:30 am - 10:00 am ET, room 104B